相似文献
1
Unraveling the Tau Puzzle: A Brief Discussion on Biomarkers in Alzheimer's Disease.
J Alzheimers Dis. 2024;100(1):41-43. doi: 10.3233/JAD-240055.
2
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Lancet Neurol. 2020 May;19(5):422-433. doi: 10.1016/S1474-4422(20)30071-5.
3
Biomarkers for Alzheimer's disease: current status and prospects for the future.
J Intern Med. 2018 Dec;284(6):643-663. doi: 10.1111/joim.12816. Epub 2018 Aug 19.
4
Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP.
Neurobiol Dis. 2023 Dec;189:106356. doi: 10.1016/j.nbd.2023.106356. Epub 2023 Nov 15.
5
Clinical significance of fluid biomarkers in Alzheimer's Disease.
Pharmacol Rep. 2020 Jun;72(3):528-542. doi: 10.1007/s43440-020-00107-0. Epub 2020 May 8.
6
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8.
7
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
8
Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Lancet Neurol. 2018 Oct;17(10):860-869. doi: 10.1016/S1474-4422(18)30285-0. Epub 2018 Aug 29.
9
Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.
Drugs Today (Barc). 2007 Jun;43(6):423-31. doi: 10.1358/dot.2007.43.6.1067341.
10
Identifying and validating biomarkers for Alzheimer's disease.
Trends Biotechnol. 2011 Jan;29(1):26-32. doi: 10.1016/j.tibtech.2010.09.007. Epub 2010 Oct 23.
本文引用的文献
1
The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
J Alzheimers Dis. 2024;98(1):13-32. doi: 10.3233/JAD-230799.
2
Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants.
Alzheimers Res Ther. 2023 Oct 13;15(1):175. doi: 10.1186/s13195-023-01314-6.
3
Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment.
J Nanobiotechnology. 2023 Feb 14;21(1):54. doi: 10.1186/s12951-023-01793-7.
4
Empowering drug development: Leveraging insights from imaging technologies to enable the advancement of digital health technologies.
Clin Transl Sci. 2023 Mar;16(3):383-397. doi: 10.1111/cts.13461. Epub 2022 Dec 2.
5
Science disconnected: the translational gap between basic science, clinical trials, and patient care in Alzheimer's disease.
Lancet Healthy Longev. 2022 Nov;3(11):e797-e803. doi: 10.1016/S2666-7568(22)00219-7.
6
The ATN Framework-Moving Preclinical Alzheimer Disease to Clinical Relevance.
JAMA Neurol. 2022 Oct 1;79(10):968-970. doi: 10.1001/jamaneurol.2022.2967.
7
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.
Alzheimers Dement. 2022 Dec;18(12):2669-2686. doi: 10.1002/alz.12756. Epub 2022 Jul 31.
8
Ethical issues in early diagnosis and prevention of Alzheimer disease.
Dialogues Clin Neurosci. 2019 Mar;21(1):101-108. doi: 10.31887/DCNS.2019.21.1/pwhitehouse.
9
Blood-based biomarkers for Alzheimer's disease-An update.
J Neurosci Methods. 2019 May 1;319:2-6. doi: 10.1016/j.jneumeth.2018.10.025. Epub 2018 Oct 25.
10
Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept.
Alzheimers Dement. 2017 Apr;13(4):454-467. doi: 10.1016/j.jalz.2016.12.003. Epub 2017 Feb 7.
Zotero 插件